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identifying potential novel drugs 
against Helicobacter pylori by 
targeting the essential response 
regulator HsrA
Andrés González  1,2, Sandra Salillas2,3, Adrián Velázquez-campoy2,4,5, Vladimir espinosa 
Angarica6, María F. fillat2,3, Javier Sancho  1,2,3 & Ángel Lanas  1,4,7,8
the increasing antibiotic resistance evolved by Helicobacter pylori has alarmingly reduced the 
eradication rates of first-line therapies. To overcome the current circulating resistome, we selected 
a novel potential therapeutic target in order to identify new candidate drugs for treating H. pylori 
infection. We screened 1120 FDA-approved drugs for molecules that bind to the essential response 
regulator HsrA and potentially inhibit its biological function. Seven natural flavonoids were identified as 
HsrA binders. All of these compounds noticeably inhibited the in vitro DNA binding activity of HsrA, but 
only four of them, apigenin, chrysin, kaempferol and hesperetin, exhibited high bactericidal activities 
against H. pylori. Chrysin showed the most potent bactericidal activity and the most synergistic effect 
in combination with clarithromycin or metronidazole. Flavonoid binding to HsrA occurs preferably at 
its C-terminal effector domain, interacting with amino acid residues specifically involved in forming 
the helix-turn-helix DNA binding motif. Our results validate the use of HsrA as a novel and effective 
therapeutic target in H. pylori infection and provide molecular evidence of a novel antibacterial 
mechanism of some natural flavonoids against H. pylori. The results further support the valuable 
potential of natural flavonoids as candidate drugs for novel antibacterial strategies.
Helicobacter pylori is considered the most prevalent human pathogen worldwide, more than half the world’s pop-
ulation is infected by this Gram-negative bacterium1. Unless treated, colonization of the human stomach usually 
persists lifelong causing gastric inflammation and contributing to the pathogenesis of peptic ulceration, gastric 
adenocarcinoma, and mucosa-associated lymphoid-tissue (MALT) lymphoma2,3. Nearly 90% of all gastric can-
cers, the third most common cause of cancer death worldwide, can be attributable to H. pylori infection1.
A standard triple therapy containing a proton-pump inhibitor (PPI) and two antibiotics, clarithromycin and 
either amoxicillin or metronidazole, has been traditionally considered the first-line regimen for treatment of 
H. pylori infection4,5. However, the PPI-based triple therapy has been described to be losing its efficacy for H. 
pylori, with eradication cure rates as low as 50% to 70%, due to high rates of antibiotic resistance, high rates of 
antibiotic-associated side effects and low compliance6,7. Because of increasing failure of the traditional therapy, 
the current guidelines recommend a quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) as 
first-line strategy, while the PPI triple therapy is restricted to areas with known low clarithromycin resistance8. In 
February 2017, the WHO included H. pylori in its first ever list of antibiotic-resistant “priority pathogens”, a cat-
alogue of 12 families of bacteria that pose at present the greatest threat to human health9. Nowadays, an effective 
novel therapy against this clinically relevant pathogen is mandatory to increase eradication rates and minimize 
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both antimicrobial resistance and side effects on normal microbiota. To mitigate the challenges of antimicrobial 
resistance, the search for new bioactive compounds able to inhibit the growth of pathogens by acting specifically 
on new molecular targets can be a valuable route for drug discovery.
The H. pylori genome harbours the hp1043 (hsrA) gene, encoding for an OmpR-like “orphan” response regu-
lator which has been shown to be essential for cell viability10,11. HsrA (for homeostatic stress regulator) is unique 
and highly conserved among members of the Epsilonproteobacteria12. The protein functions as a global home-
ostatic regulator synchronizing metabolic functions and virulence with availability of nutrients and cell divi-
sion13, mediating also the response to oxidative stress14. HsrA binds to DNA acting as a transcriptional activator, 
modulating its own expression15, but also the expression of a plethora of genes involved in crucial cellular func-
tions such as translation, transcription, energy metabolism, nitrogen metabolism and redox homeostasis14,16. 
NMR-spectroscopy and X-ray crystallography analyses proposed that HsrA exists as a symmetric dimer in vivo 
with two well-defined functional domains, an N-terminal regulatory domain and a C-terminal DNA-binding/
effector domain17. Unlike most response regulators, where phosphorylation of the regulatory domain triggers 
conformational changes that promote dimerization of the protein and activate its DNA binding function, the 
two domains of HsrA seems to act independently. Thus, mutations in the N-terminal regulatory domain that 
inhibited dimerization did not affect DNA binding function17, while deletion of the C-terminal effector domain 
did not have effect on the dimerization ability of the protein15. Attempts to both deletion and overexpression of 
HsrA have resulted unsuccessful, supporting not only an essential function of the regulator but also a very tight 
post-transcriptional control of its expression that ensures appropriate levels of the protein into the cell12,15.
As an essential protein for microbial viability, easily produced under lab conditions, with a known crystal 
structure and no counterpart in humans, the response regulator HsrA become in a promising therapeutic target 
against H. pylori infection. In the present study, we screened the Prestwick Chemical Library®, a collection of 
1120 FDA-approved, off-patent small molecules for compounds that specifically bind to HsrA and potentially 
inhibit its essential function. Four HsrA inhibitors, the natural flavonoids apigenin, chrysin, kaempferol and 
hesperetin exhibited strong bactericidal activities against both metronidazole- and clarithromycin-resistant H. 
pylori strains.
Materials and Methods
Chemicals. The Prestwick Chemical Library was purchased from Prestwick Chemical (France). All drugs 
were provided as 10 mM solutions in 100% DMSO in 96-well plates, which were stored at −20 °C until use. For 
some assays, compounds of interest were purchased from Sigma-Aldrich and properly stored according to the 
manufacturer indications. Stock solutions of each compound were prepared at 20 mM in 100% DMSO for EMSA 
and ITC, and at 10.24 g/L in 100% DMSO for MIC/MBC determinations. In all cases, stock solutions of drugs 
were stored at −20 °C.
Recombinant HsrA expression and purification. The complete sequence of gene hsrA (hp1043) 
was amplified from the genomic DNA of H. pylori strain 26695 (ATCC 700392) using the oligonucleo-
tides Hpylori.hsrA_up (5′- GGAATTCCATATGCGCGTTCTACTGATTG-3′) and Hpylori.hsrA_dw 
(5′-CCCAAGCTTTTACTCTTCACACGCCGG-3′). The resulting PCR product was digested with NdeI and 
HindIII, and inserted between the same restriction sites of vector pET-28a (Novagen). The final vector was par-
tially sequenced to ensure that no modifications in the nucleotide sequence occurred during PCR and clon-
ing. N-terminal 6 × His-tagged HsrA was overexpressed in E. coli BL21(DE3) (EMD Biosciences). Recombinant 
E. coli carrying the pET-28a-hsrA vector was grown to late log phase (OD600 = 0.6–0.8) in Luria Bertani (LB) 
broth at 37 °C with vigorous shaking. At this time, hsrA expression was induced by addition of 1 mM IPTG 
(isopropyl-β-D-thiogalactopyranoside) and culture was further incubated by 6 h. Cells were harvested by centrif-
ugation at 8,000 rpm for 10 min at 4 °C, washed twice with ice-cold PBS (pH 7.4) and stored at −20 °C.
For protein purification, cells were resuspended in ice-cold lysis buffer containing 50 mM Tris-HCl (pH 8), 
500 mM NaCl, 10 mM imidazole, 1 mM PMSF (phenylmethylsulfonyl fluoride) and sonicated in an ice-water bath 
by ten 30 s bursts with 30 s cooling intervals. The resulting crude extracts were centrifuged twice at 15,000 rpm for 
20 min at 4 °C to remove cell debris. Recombinant His-tagged HsrA was purified by immobilized metal-affinity 
chromatography (IMAC) using nickel charged Chelating Sepharose Fast Flow resin (GE Healthcare). The 
bound protein was eluted by using an imidazole gradient (10 mM to 1 M) and dialyzed against the store buffer 
(50 mM Tris-HCl [pH 8], 300 mM NaCl, 10% glycerol). Protein concentration was determined using the BCA™ 
Protein Assay kit (Thermo Fisher Scientific). The N-terminal His-tag was removed by overnight treatment of 
the 6 × His-tagged HsrA with thrombin (GE Healthcare), 10 units of enzyme for each mg of tagged protein. The 
cleaved HsrA protein was obtained in the flow throw of a second IMAC-Ni2+ purification step.
High-throughput screening. A target-based high-throughput screening (HTS) methodology was used to 
test the Prestwich Chemical Library for compounds that specifically bind to H. pylori HsrA regulator and poten-
tially inhibit its biological function. Compound binding to HsrA was assessed by a fluorescence-based thermal 
shift assay18,19. The screening was performed in V-shape 96-well plates Thermo-Fast 96 (ABgene), adding a final 
volume of 100 μL of reaction mixture in each well of the plate. A solution of 10 µM of recombinant HsrA was 
freshly prepared in a buffer containing 50 mM Tris-HCl [pH 8], 150 mM NaCl, 10% glycerol and 5 mM DTT. The 
SYPRO® Orange ready-to-use fluorescent stain (Thermo Fisher Scientific) was added to this protein solution at 
a final concentration of 10X and thoroughly mixed. Next, 97.5 μL of this reaction mixture was dispensed into all 
the wells of a V-shape 96-well plate. While all wells of the columns 1 and 12 received 2.5 μL of DMSO (vehicle) 
instead of compounds and were used as reference controls, each of the eighty wells of columns 2 to 11 in the 
96-well plate received 2.5 μL of a different compound from the chemical library (250 μM as final concentration 
each). After mixing, each well of the plate was overlaid with 50 μL of mineral oil to avoid evaporation. Unfolding 
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curves were registered from 25 °C to 75 °C in 1 °C steps using a FluoDia T70 High Temperature Fluorescence 
Microplate Reader (Photon Technology International, UK). The system was allowed to equilibrate at each tem-
perature for 1 min before each fluorescence acquisition. In practice, this represents an operational heating rate of 
0.25 °C/min approximately. Because SYPRO Orange dye interacts with hydrophobic regions in the protein that 
become exposed upon denaturation, fluorescence emission of the dye serves as a read out of thermal denaturation 
of the protein20. The unfolding curves corresponding to each well were analysed using a homemade software that 
estimates the midpoint temperature of unfolding (Tm) of each well. Compounds that increased thermal stability 
of HsrA above the twofold standard deviation value of reference controls were identified as HsrA binders and 
selected as potential inhibitors.
Electrophoretic mobility shift assays. The DNA binding activity of the recombinant HsrA response 
regulator as well as its putative inhibition by HsrA binders were evaluated by electrophoretic mobility shift assays 
(EMSAs). A 300-bp promoter region of porGDAB operon was amplified by PCR and used as target sequence of 
HsrA in all EMSA experiments14. Recombinant HsrA protein (6 μM) was mixed with 120 ng of target promoter 
in a 20 μL reaction volume containing 10 mM bis-Tris (pH 7.5), 40 mM KCl, 100 mg/L BSA, 1 mM DTT, and 
5% glycerol. During the inhibition assays, putative inhibitors were added to final concentrations of 2, 1, 0.5 and 
0.1 mM to the mixtures of protein and DNA. Binding assays with DMSO instead of inhibitors were included as 
vehicle controls. To ensure the specificity of EMSAs, a 150-bp DNA fragment corresponding to the coding region 
of gene pkn22 (alr2502) from Anabaena sp. PCC 7120 was included as non-specific competitor DNA in all assays. 
Mixtures were incubated at room temperature for 20 min and subsequently separated on a 6% non-denaturing 
polyacrylamide gel in running buffer (25 mM Tris, 190 mM glycine) at 90 V. The gel was stained with SYBR Safe 
DNA gel stain (Invitrogen) and processed with a Gel Doc 2000 Image Analyzer (Bio-Rad).
Minimal inhibitory and bactericidal concentrations. The antibacterial activity of HsrA inhibitors was 
tested against three different strains of H. pylori: ATCC 700392, ATCC 43504 (metronidazole-resistant reference 
strain), and ATCC 700684 (clarithromycin-resistant reference strain). MIC determinations were carried out by 
the broth microdilution method as previously described18,21, with slight modifications. H. pylori strains were 
grown in Blood Agar Base N°2 (OXOID) supplemented with 8% defibrinated horse blood (OXOID) in a humid-
ified microaerobic incubator (85% N2, 10% CO2, 5% O2) at 37 °C for 72 h. To prepare inoculums for MIC assays, 
bacteria were grown for 48 hours at 37 °C in brain heart infusion broth supplemented with 4% FBS (BHI + FBS) 
and next diluted in the same fresh medium to a final optical density at 660 nm of 0.01 (∼106 CFU/mL). From 
this inoculum, 195 µL were added to all wells of the first column of a sterile 96-well flat-bottom microtiter plate, 
while 100 µL were added to all wells from column 2 to 12. Next, 5 µL of a 10.24 g/L in 100% DMSO stock solution 
of each HsrA inhibitor were added to wells of the first column and two-fold serial dilutions were performed in 
order to test each inhibitor in a concentration range from 256 to 0.125 mg/L. DMSO, metronidazole and clar-
ithromycin were included as controls in all assays. Plates were incubated under microaerobic conditions at 37 °C 
and examined visually after 72 h22,23. MIC values were defined as the lowest concentration of compound that 
completely inhibited the visible growth of bacteria after 72 h incubation. For MBC determinations, 10 μL aliquots 
of two compound dilutions around the MIC value were seeded on Blood Agar Base N°2 supplemented with 8% 
defibrinated horse blood and incubated for 72 h under microaerobic conditions at 37 °C. MBC was defined as the 
lowest concentration of compound that prevented the growth of ≥99.9% of H. pylori cells after subculture on the 
inhibitor-free medium. Each experiment was performed twice in triplicate to confirm the results.
Time-kill kinetics assays. Time-kill kinetics of selected flavonoids were carried out as previously 
described18 with slight modifications. A final concentration of 2 × MIC from each flavonoid was mixed with 
200 µL of H. pylori strain ATCC 700684 at 1.0 × 105 CFU/mL in BHI + FBS. The experiments were performed 
twice in triplicate using sterile 96-well flat-bottom microtiter plates. Plates were incubated under microaerobic 
conditions at 37 °C with shaking. Mixtures of bacteria with the same amount of DMSO (vehicle) instead flavo-
noid were incubated under the same conditions and included as controls in all determinations. Aliquots of 20 µL 
taken at time intervals of 0, 2, 4, 8, and 24 h were serially diluted in BHI medium and plated in Blood Agar Base 
N°2 supplemented with 8% defibrinated horse blood nutrient agar for colony forming unit (CFU) determination. 
Plates were incubated at 37 °C for 72 h under microaerobic conditions. The amount of grown H. pylori colonies 
was counted and presented as log10 CFU/mL versus incubation time. The results were subjected to statistical 
analysis using the Mann-Whitney U test24. The criterion P < 0.1 was used to determine the statistical significance.
Checkerboard assay. The existence of synergism in the antimicrobial activity of selected flavonoids 
and the first-line antibiotics clarithromycin and metronidazole was determined against two H. pylori strains 
(clarithromycin-resistance strain ATCC 700684 and metronidazole-resistant strain ATCC 43504) using the 
checkerboard assay25,26.
Solutions at 4-fold the highest concentration to be tested were prepared for each compound. Then, antibiotic 
and flavonoid were two-fold serially diluted in BHI + FBS using two sterile 96-well flat-bottom microtiter plates; 
one of the compounds was diluted along the rows (horizontally) of a first plate, and the other compound was 
diluted along the columns (vertically) of the second plate. A matrix of both gradient was obtained by mixing 
50 µL of the content of each well of plate 1 (except from first column) with 50 µL from the same well of plate 2 
(except from last row), thereby diluting both compounds at two-fold the concentrations to be tested. Thus, the 
first column in plate 3 would have serial dilutions of just one of the compounds, and the last row would have serial 
dilutions of the other. Finally, 100 µL of freshly prepared inoculum (2×106 CFU/mL) of proper H. pylori strain 
were added to all wells. The plates were incubated for 72 h at 37 °C under microaerophilic conditions. Then, 30 µL 
of 0.1 mg/ml filter-sterilized resazurin (Sigma-Aldrich) was added as growth indicator25,27 to each well and plates 
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were further incubated for 8 hours. Each tested panel was performed in duplicate. The interaction between the 
tested antimicrobial agents was determined by calculating the fractional inhibitory concentration (FIC) index. In 
the 96-well plate, the first column shows the MIC of one of the compounds (A), and the last row shows the MIC of 
the second compound (B). FIC index could be calculated as: FICA (MICA in the presence of B/MICA alone) + FICB (MICB in 
the presence of A/MICB alone). The FIC index allows objective identification of any interaction between two compounds 
against a particular bacterial strain, indicating whether there is synergy (FIC index ≤0.5), additive effect (FIC 
index >0.5 to ≤1), no interaction or neutral (FIC index >1 to ≤4), or antagonism (FIC index >4)26,28,29. The term 
“synergy” implies that the resulting effect of a combination is significantly greater than the sum of its individual 
parts, while “additive effect” occurs when substances added together will improve or increase their efficacies, 
albeit not to the extent of a synergistic interaction30.
Isothermal titration calorimetry assays. Direct interaction of the selected compounds with HsrA was 
assessed by isothermal titration calorimetry (ITC). Titrations were performed in a high-sensitivity AutoiTC200 
microcalorimeter (MicroCal, Malvern Instruments). Protein samples and compound solutions were properly 
degassed and carefully loaded into the calorimetric cells to avoid bubble formation during stirring. Experiments 
were performed with freshly prepared buffer-exchanged protein solutions, at 25 °C in 50 mM Tris-HCl [pH 8], 
150 mM NaCl, 10% glycerol, 1% DMSO. A solution of HsrA (20 µM) in the calorimetric cell was titrated with a 
solution of the corresponding compound (200 µM) located in the injecting syringe. A sequence of 19 injections of 
2 µL volume was programmed with a time spacing of 150 s, a stirring speed of 750 rpm, and a reference power of 
10 µcal/s in the sample cell31,32. The binding isotherm (ligand-normalized heats as a function of the molar ratio) 
was obtained through integration of the individual heat effect associated with each ligand injection observed in 
the thermogram (thermal power required to maintain the difference between the temperatures of the sample cell 
and the reference cell close to zero as a function of time). Dissociation constants and binding enthalpies were 
calculated by non-linear least squares regression data analysis in Origin 7.0 (OriginLab).
Molecular docking. The tridimensional structures of flavonoids (ligands) were downloaded from 
PubChem33 and were docked onto the structure of the H. pylori HsrA response regulator (2HQR, model 1, chain 
A) obtained from the PDB34, using AutoDock Vina35. The ligands were considered flexible, and a ligand-specific 
torsion tree was defined in each case, representing the rigid and rotatable pieces of the molecule. In each torsion 
tree rotatable bonds were allowed the torsional degrees of freedom corresponding to the specific bond, according 
to AutoDock torsion parameterizations. The structure of the protein was considered rigid and a grid enclosing the 
whole structure of the protein was defined, representing the search space for putative interaction sites. Separately, 
pre-calculated maps were defined for the ligands, encompassing independent maps for each atom type in the 
ligand, combining the desolvation and electrostatics potentials. The AutoGrid algorithm was then used to esti-
mate the interaction energy of a ligand conformation (i.e. ligand pose) by summing up the contribution of atoms 
of a specific element at each point in the grid around the rigid receptor. After scanning the whole protein structure 
search space, the docking solutions passing a threshold of ΔG < −4.0 kcal/mol were ranked based on the esti-
mated interaction energy. The top ranking pose for each ligand was selected as predicted model of interaction.
Results
High-throughput screening of Prestwick Chemical Library reveals specific flavonoid binders 
of H. pylori HsrA response regulator. As the first step to identify new candidate drugs for treating H. 
pylori infection, we screened the Prestwich Chemical Library for small FDA-approved molecules that specifically 
bind to the essential response regulator HsrA. The HTS was carried out using a fluorescence-based thermal shift 
assay18,19. With this method, any compound of the chemical library that preferentially binds to the native state of 
HsrA increases the protein conformational stability and causes a shift of the protein unfolding curve to higher 
temperatures due to the increased melting temperature (Tm) of the protein-binder complex. To minimize the 
identification of false-positive binders, we defined as relevant compounds those which increased the thermal 
stability of HsrA above the twofold standard deviation of Tm value of reference controls. Following this selection 
criterion, the target-based HTS approach identified 14 compounds of the 1120 compound collection (1.25%) as 
HsrA binders. Notably, seven of these positive hits consisted in naturally occurring flavonoids, including api-
genin, chrysin, hesperetin, kaempferol, luteolin, myricetin, and quercetin (Table 1). The increases in Tm values 
indicated that all of these seven natural flavonoids bound to HsrA and formed stable complexes. The thermal 
upshifts of the HsrA unfolding curve triggered by 250 μM of four different flavonoids (chrysin, apigenin, hes-
peretin and kaempferol) are shown in Fig. 1. Due to the high heterogeneity of the rest of HsrA binders (data not 
shown), we focused our further analyses to primarily discern the potentiality of flavonoid binders of HsrA as 
phytochemical therapies to H. pylori infections.
Flavonoids inhibit DNA binding activity of HsrA in vitro. HsrA is an orphan response regulator that 
functions as a transcriptional activator of gene expression; hence, it interacts with DNA and binds to specific 
sequences located in target promoters. Biological activity of purified recombinant HsrA was evaluated before 
its use in the target-based HTS in order to ensure that the native conformation of the response regulator inter-
acts with potential inhibitors of the chemical library. EMSA analyses of the recombinant response regulator 
in the presence of its target promoter PporGDAB14 demonstrated a high affinity of HsrA by its target DNA in a 
concentration-dependent manner (Fig. 2A). Under the experimental conditions used in EMSAs, 120 ng of target 
DNA were completely and specifically complexed to HsrA from 6 μM of the recombinant protein. Hence, this 
concentration was subsequently used for EMSA inhibition assays in the presence of flavonoid binders.
To determine whether the flavonoid binders previously identified with our screening approach effec-
tively inhibit the DNA binding activity of HsrA, we carried out EMSA analyses in the presence of different 
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concentration of each flavonoids (from 2 mM to 100 μM). Since flavonoids were diluted in 100% DMSO, negative 
controls of EMSAs were carried out by mixing the same amounts of protein and DNA in the presence of DMSO 
instead of flavonoids. As shown in Fig. 2B, all flavonoids appreciably inhibited the in vitro binding activity of 
HsrA to its target promoter. However, the in vitro inhibitory effects of some flavonoid binders such as apigenin or 
chrysin on the DNA binding activity of HsrA appeared noticeable stronger than those exerted by other flavonoids 
such as quercetin.
Apigenin, chrysin, kaempferol and hesperetin exhibit potent bactericidal activity against H. 
pylori. To evaluate the antibacterial activity of the HsrA inhibitors, we determined both MIC and MBC values 
of each HsrA inhibitors against three different strains of H. pylori, including the metronidazole-resistant strain 
Compound
ΔTm 
(°C)a Class Chemical structure Pharmacological effects
chrysin 1.8 flavone anti-inflammatory, antineoplastic, antioxidant, hepatoprotector
apigenin 3.9 flavone antiproliferative, anti-inflammatory
luteolin 1.8 flavone anti-inflammatory, antioxidant, antiproliferative
hesperetin 2.1 flavanone cholesterol lowering, hypolipidemic, antioxidant, anti-allergic, antineoplastic, anti-inflammatory
kaempferol 2.6 flavonol anti-inflammatory, diuretic, antioxidant
quercetin 4.2 flavonol antioxidant, anti-allergic, anti-inflammatory, antiproliferative
myricetin 3.9 flavonol antineoplastic, antioxidant, hypoglycemic
Table 1. HsrA binders identified by a fluorescence-based HTS method using the thermal shift assay. aIncrease 
in the Tm value of protein-ligand complex with respect to the mean Tm value of controls (protein + DMSO). In 
all cases, ΔTm > twofold standard deviation of controls.
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ATCC 43504 and the clarithromycin-resistant strain ATCC 700684. In all cases, the lowest concentration of com-
pound that completely inhibited the visible growth of bacteria after 72 h incubation was also the same which 
prevented the growth of ≥99.9% of H. pylori cells after subculture on the inhibitor-free medium (Table 2). Thus, 
both MIC and MBC values corresponded to the same concentration of compound for all the HsrA inhibitors 
tested. Despite all the seven natural flavonoids specifically bound to HsrA and inhibited its biological function in 
vitro according to EMSA, only four of them, apigenin, chrysin, kaempferol and hesperetin, exhibited potent bac-
tericidal activities (MBC ≤ 8 mg/L) against H. pylori. Hence, the bactericidal effect of the other three HsrA inhib-
itors, luteolin, quercetin, and myricetin were evidenced at concentrations quite higher than MIC breakpoints for 
antimicrobials traditionally used in anti-H. pylori therapies36,37, thereby these three flavonoids were considered 
poorly active against H. pylori. To further evaluate the bactericidal activities of apigenin, chrysin, kaempferol and 
hesperetin against H. pylori, time-kill kinetics were carried out at 2 × the MIC values (listed in Table 2) for each 
compound against the H. pylori strain ATCC 700684. As in shown Fig. 3, no live bacteria could be detected at 
8 hours after exposition to 2 × MIC of each flavonoid, and this was found to be statistically significant according 
to the Mann-Whitney U test24 (P < 0.1). The bactericidal activity of chrysin at this concentration was significant 
(P < 0.1) even after only 4 hours of exposition to the microorganism.
The in vitro interactions of the two flavonoids that exhibited the most potent bactericidal activities, chrysin 
and hesperetin (Table 2), with antibiotics commonly used as first-line H. pylori eradication therapies were ana-
lysed. As shown in Table 3, the combinations of flavonoids with antibiotics inhibited the growth of H. pylori at 
a lower concentration than when each single compound was assayed separately. In all cases, the combination of 
chrysin or hesperetin with clarithromycin or metronidazole showed a synergistic or additive antimicrobial effect 
against the two antibiotic-resistant strains used in the assays. Notably, chrysin reduced the MIC value of clarithro-
mycin up to 8 times (FIC = 0.125) in the clarithromycin-resistant strain ATCC 700684, and up to 16 times the 
MIC value of metronidazole (FIC = 0.0625) in the metronidazole-resistant strain ATCC 43504 (Table 3).
Bactericidal flavonoids interact with the C-terminal effector domain of HsrA. ITC and molecular 
docking analyses were carried out in order to analyze the binding affinity of bactericidal flavonoids (apigenin, 
chrysin, kaempferol and hesperetin) for the target protein as well as to understand the structural basis of this 
Figure 1. Thermal upshifts of the HsrA unfolding curve triggered by 250 μM of the natural flavonoids chrysin, 
apigenin, hesperetin and kaempferol. The HTS was carried out using a fluorescence-based thermal shift assay. 
Any compound that preferentially binds to the native state of HsrA would increase the protein stability and 
cause an upshift of the protein unfolding curve due to the increased melting temperature (Tm) of the protein-
binder complex. In all assays, DMSO (vehicle) instead of compounds were mixed with the protein and used as 
reference control of the protein unfolding curve.
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interaction. The ITC data indicated dissociation constants in the micromolar range in all cases, while complexes 
of a 1:1 stoichiometry were observed for all flavonoids (Table 4, Fig. 4). Thus, each HsrA monomer appeared to 
bind one molecule of flavonoid.
Figure 2. Impact of several natural flavonoids on the in vitro affinity of HsrA for its target promoter. (A) 
EMSAs showing the ability of HsrA to specifically bind in vitro the promoter region of porGDAB operon. 
DNA fragments were mixed with increasing concentrations of recombinant HsrA protein (indicated in μM) 
and separated on a 6% PAGE. A 150-bp DNA fragment of Anabaena gene pkn22 was included as non-specific 
competitor DNA in all assays. (B) DNA fragments were mixed with 6 μM of recombinant HsrA protein in the 
presence of 2, 1, 0.5 and 0.1 mM of natural flavonoids.
8Scientific RepoRtS |         (2019) 9:11294  | https://doi.org/10.1038/s41598-019-47746-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
As shown in Fig. 5, flavonoid binding to the native conformation of HsrA occurs preferably at the C-terminal 
effector domain, as predicted by molecular docking analyses. Notably, the predicted binding site for chrysin 
differed from those occupied for the other three flavonoids. However, the best binding poses for all bactericidal 
flavonoids appeared to interact with amino acid residues specifically involved in forming the helix-turn-helix 








chrysin 8 (8) 8 (8) 4 (4)
apigenin 8 (8) 8 (8) 8 (8)
luteolin 64 (64) 32 (32) 64 (64)
hesperetin 8 (8) 8 (8) 4 (4)
kaempferol 8 (8) 16 (16) 16 (16)
quercetin 64 (64) 64 (64) 64 (64)
myricetin 128 (128) 128 (128) 128 (128)
metronidazole 1 (2) 64 (128) 1 (2)
clarithromycin ≤0.12 (≤0.12) ≤0.12 (≤0.12) 8 (16)
Table 2. Minimal inhibitory and bactericidal concentrations of HrsA inhibitors. MTZ-R, metronidazole 
resistant strain. CLR-R, clarithromycin resistant strain.
Figure 3. Time-kill kinetics of natural flavonoids chrysin, apigenin, hesperetin and kaempferol against H. pylori 
strain ATCC 700684. Bacterial counts were determined at time zero and after 2, 4, 8, and 24 hours of incubation 
with two times the MIC. Mixtures of bacteria with DMSO (vehicle) instead flavonoid were used as controls. 
Values are the averages of three independent determinations; vertical bars represent standard deviations. Please 
note that in some instances the error is smaller than the symbols used.




CLR + chrysin 0.125 0.25 0.375 synergy




MTZ + chrysin 0.0625 0.0625 0.125 synergy
MTZ + hesperetin 0.25 0.25 0.5 synergy
Table 3. Interaction of the natural flavonoids chrysin and hesperetin with antibiotics of first-line Helicobacter 
pylori eradication therapies in two H. pylori resistant strains. aFractional inhibitory concentration (FIC) index 
could be calculated as: FICA (MICA in the presence of B/MICA alone) + FICB (MICB in the presence of A/MICB alone). bAccording 
to the FICI value, the interaction between two compounds against a particular bacterial strain can be classified 
as: synergy (FICI ≤ 0.5), additive (FICI > 0.5 to ≤1), no interaction or neutral (FICI > 1 to ≤4), and antagonism 
(FICI > 4).
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Discussion
The dramatic increase in bacterial resistance to antibiotics belonging to all pharmacological classes constitutes a 
major worldwide health concern and it must be a priority to the scientific community38. An important challenge 
in the current antibiotic resistance crisis is the identification of novel microbial targets, essential for in vivo growth 
or pathogenicity, whose inhibitors can overcome the currently circulating resistome of human pathogens. Among 
the plethora of genes indispensable for in vivo growth and virulence of bacterial pathogens, transcriptional reg-
ulators (TRs) stand out because of the potential multitargeting effect of anti-TR molecules on cellular virulence 
and physiology39.
In H. pylori, the essential response regulator HsrA appears as a promising target for drug development11–16. In 
the present study, we carried out an affinity-based HTS18,19 of the Prestwick Chemical Library for FDA-approved 
molecules that specifically bind to the HsrA response regulator and potentially inhibit its essential biological 
function. By using this screening methodology, seven natural flavonoids including apigenin, chrysin, hesperetin, 
kaempferol, luteolin, myricetin, and quercetin were identified as HsrA binders, since all of them significantly 
increased its thermal stability. All flavonoids identified as HsrA binders appreciably inhibited the DNA binding 
activity of HsrA in vitro according to EMSA; however, only four of them, apigenin, chrysin, kaempferol and 
hesperetin, exhibited potent bactericidal activities against three different strains of H. pylori, including strains 
resistant to metronidazole and clarithromycin. Notably, the flavonoids with two or more hydroxyl groups in ring 
B (luteolin, quercetin, myricetin) showed moderate to low bactericidal activities against H. pylori. Since more 
hydroxyl groups results in lower hydrophobicity40, the lowest bactericidal activity of myricetin despite its HsrA 
inhibitory effect could be the result of poor translocation across the cell membrane. Among all the flavonoids 
evaluated in this work, the flavone chrysin showed the most potent bactericidal activity and the most synergis-
tic effect in combination with antibiotics of first-line H. pylori eradication therapies. Notably, chrysin strongly 
synergized with both clarithromycin and metronidazole, supporting its valuable potential as adjuvant in cur-
rent combinatory therapies, especially in the treatment of refractory H. pylori infections or multidrug-resistance 
isolates41,42.
HsrA functions as a symmetric dimer in vivo with two well-defined functional domains in each monomer, 
an N-terminal regulatory domain (residues 1 to 119) and a C-terminal DNA-binding/effector domain (residues 
120 to 223)17. In contrast to most response regulators, the two domains of HsrA seem to act independently, 
and mutations in the N-terminal regulatory domain did not appreciably affect DNA binding function17. Each 
monomer of HsrA contains eight α-helices and twelve β-strands, where two α-helices in the C-terminal effec-
tor domain (α7 and α8, comprising the residues 165 to 199) form the HTH DNA binding motif. In fact, single 
mutations at the amino acid residues involved in forming the HTH motif or its periphery noticeably inhibited 
or completely destroyed the DNA binding ability of the protein17. Molecular docking analyses suggested that the 
bactericidal flavonoids apigenin, chrysin, kaempferol and hesperetin bind to HsrA preferably in its C-terminal 
effector domain, interacting with several amino acids involved in both the structure of the HTH motif and the 
domain stabilization. According to these in silico predictions, the HsrA activity inhibition by flavonoids could 
be the result of direct blockage of key amino acid residues involved in protein-DNA interaction and/or confor-
mational changes in the effector domain that destabilize the regulator binding to target promoters. In fact, one 
of the molecular mechanisms associated to the antibacterial action of flavonoids is the formation of complexes 
with proteins through different forces such as hydrogen bonding, hydrophobic interactions and covalent bonds, 
thereby inactivating microbial adhesins, enzymes, transport proteins, and other cell targets43.
Flavonoids comprise a wide class of compounds with variable phenolic structures, mostly found in plants44. 
Both medicinal plants and flavonoid rich extracts have been used for centuries to treat human pathologies45,46, 
including H. pylori infection and related diseases47–50. A large number of studies have demonstrated the strong 
antibacterial activity of natural, semisynthetic51 and synthetic flavonoids52; however, their mechanisms of action 
remain poorly characterized. In H. pylori, flavonoids have been found to inhibit enzymatic activities such as 
urease53, DNA gyrase48, dihydrofolate reductase48, N-acetyltransferase54, D-alanine:D-alanine ligase55, and 
β-hydroxyacyl-acyl carrier protein dehydratase56. Quercetin inhibited vacuolation and caspase-3 activation in 
HeLa cells induced by the vacuolating cytotoxin A, protecting from gastric inflammation and apoptosis associated 
with H. pylori infection57,58. Kaempferol decreased transcription of type IV secretion system (T4SS) components 
involved in CagA injection and secretion system subunit protein A (SecA) of type V secretion system (T5SS) 
involved in VacA secretion, thereby producing an anti-inflammatory effect by suppressing the translocation of 












chrysin 0.77 17 −4.1 −6.5 P181, K165, I184
apigenin 0.81 20 −3.8 −6.4 P198, I135, K194, V144, G146, K145, L152
hesperetin 0.83 26 −5.8 −6.2 P198, M195, I191, K194, P148, V144, K145, G146, L152
kaempferol 0.78 33 −8.6 −6.1 Y137, K194, P148, G146
Table 4. Analyses of the interaction between HsrA and its bactericidal inhibitors by isothermal titration 
calorimetry and molecular docking. aAbsolute error in n is 0.06, relative error in Kd is 40%, absolute error in 
ΔH is 0.4 kcal/mol, absolute error in ΔG is 0.2 kcal/mol. bAmino acid residues directly involved in forming the 
helix-turn-helix (HTH) DNA binding motif of HsrA are highlighted in bold fonts.
1 0Scientific RepoRtS |         (2019) 9:11294  | https://doi.org/10.1038/s41598-019-47746-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
gerbils60, while hesperetin appears to damage the cell membrane triggering bacterial lysis51. Notably, the results 
of different studies conducted to decipher the mechanisms of action of flavonoids as antimicrobial agents suggest 
that a single flavonoid molecule could have multiple targets in the cell, triggering bacterial death or virulence 
decrease by inhibiting and/or affecting the activities of several biomolecules at the same time. Thus, apigenin, 
one of the HsrA inhibitors and potent anti-H. pylori bactericidal flavonoid identified in this work, also functions 
as inhibitor of the enzymes D-alanine:D-alanine ligase55 and β-hydroxyacyl-acyl carrier protein dehydratase56. 
Similarly, the lipophilic flavonoid hesperetin inhibited HsrA activity but also affected the integrity of H. pylori cell 
Figure 4. Isothermal titration calorimetry analyses of the H. pylori HsrA response regulator interactions with 
the natural flavonoids chrysin, apigenin, hesperetin and kaempferol. In the figures, upper panels show the ITC 
thermograms while lower panels show the binding isotherms.
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membrane51. In the last years, flavonoids have gained attention not only for its well-documented antimicrobial 
action, but also because some of these natural compounds manifest ability to reverse the antibiotic resistance in 
certain pathogens and enhance the action of some current antibiotic drugs61–63. Hence, combinatory therapies 
that take advantage of the clear evidences of synergism between flavonoids and several conventional antibiotics is 
now considered a promising strategy in the clinical therapy of infections with antibiotic-resistant microorganisms 
such as methicillin-resistance Staphylococcus aureus (MRSA)64.
Overall, the results of the present study validate the use of the response regulator HsrA as a novel and effective 
therapeutic target in H. pylori infection and further support the great potential of natural flavonoids as phar-
maceutical candidates for novel antibacterial or antivirulence chemotherapies. In addition, our results provide 
molecular evidence of a novel antibacterial mechanism of some natural flavonoids against H. pylori infection and 
demonstrate that this mechanism of action efficiently overcome the strategies evolved by this pathogen to evade 
the effect of first-line eradication therapies such as metronidazole and clarithromycin.
Data Availability
Materials, data and protocols are presented within the manuscript.
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